Lyme Neuroborreliosis Presenting with Propriospinal Myoclonus An

Total Page:16

File Type:pdf, Size:1020Kb

Lyme Neuroborreliosis Presenting with Propriospinal Myoclonus An 420 Letters to the Editor The physiological response to hypother- headache and fever. Walking was difficult, ments. Apart from the myoclonus, no other J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.61.4.420 on 1 October 1996. Downloaded from mia is controlled by the hypothalamus, although she felt better when standing. She evidence of spinal cord disease was appar- involving peripheral vasoconstriction and had a mild motor deficit in the proximal part ent. The treatment of the Borrelia rapidly shivering. In hypothalamic hypothermia of the lower limbs, patellar tendon reflexes relieved the pain and dramatically sup- these systems fail with loss of reactive abolished on the right, diminished on the pressed the myoclonus. peripheral vasoconstriction to reduce heat left, normal ankle reflexes, plantar reflexes V DE LA SAYETTE S SCHAEFFER loss and loss of the shivering response to flexor, and axial muscles and neck were not C QUERUEL produce heat. It is the failure of these sys- rigid. Results from routine laboratory inves- F BERTRAN tems that contributes to the hypothermia tigations were normal. Ketoprofene, G DEFER Service de Neurologie and also produces diagnostic difficulty, with haloperidol, clorazepate, and then tiaprid, P HAZERA the patient feeling warm to the touch and paracetamol, and buprenorphine were tried E GALLET not shivering. The ECG showing the with negligible relief. On 19 October, she Service de Rianimation midicale et maladies pathognomonic J waves, with absence of was transferred to the intensive care unit. infectieuses, CHU Caen, France shiver waves mirrored the hypothalamic The painful jerks were flexor, simultaneous Correspondence to: Dr V de la Sayette, Service de cause of the hypothermia. in all the muscles, and spontaneous or neurologie, CHU C6te de Nacre F 14033 Caen This is the first description of hypother- induced consistently by flexion of the neck, cedex, France. mia in a patient with multiple sclerosis with without involvement of the face and superior 1 Viader F, Poncelet AM, Chapon F, et al. Les a proved hypothalamic plaque and no other limbs. The intervals between the jerks formes neurologiques de la maladie de identifiable cause for hypothermia. became so short that the paroxyms gave the Lyme. Rev Neurol 1989;145:362-8. impression of being attacks of sustained 2 Stiernstedt GT, Granstom M, Hedrstedt B, We thank David Hughes for the preparation of the Skoldenberg B. Diagnosis of spirochetal histopathological photographs. truncal flexion. An EEG during jerking was meningitis by enzyme-linked immunoasor- unremarkable. Finally, the patient was bent assay and indirect immunofluorescence S EDWARDS anaesthetised and ventilated artificially. The assay in serum and cerebrospinal fluid. J Clin G LENNOX Microbiol 1985;21:819-25. K ROBSON treatment was propofol, fentanyl, and mus- 3 Brown P, Thompson PD, Rothwell JC, Day A WHITELEY cle relaxant pancuronium. Ceftriaxone (2 g BL, Marsden CD. Axial myoclonus of pro- Department ofNeurology, intravenously daily) was given for 14 days. priospinal origin. Brain 1991;114: 197-214. Queen's Medical Centre, Nottingham The CSF contained 398 mononuclear 4 Brown P, Thompson PD, Rothwell JC, Day BL, Marsden CD. Paroxysmal axial spasms Correspondence to: Dr S Edwards, Department of cells/,ul, numerous atypical cytological fea- of spinal origin. Mov Dis 1991;6:43-8. Academic Neurology, Queen's Medical Centre, tures, normal glucose and chloride ratios, 5 Martin R, Meinck HM, Schulte-Mattler W, Nottingham, NG7 2UH, UK. increased protein content (1 -2 g/l), intrathe- Ricker K, Mertens HG. Borrelia Burgdorferi and three myelitis presenting as a partial stiff man syn- 1 Benarroch EE. The central autonomic net- cal synthesis of IgG and IgM, drome. JNeurol 1990;237:51-4. work: functional organisation, dysfunction, oligoclonal bands were detected. The titre of and perspective. Mayo Clin Proc 1993;68: antibodies to Borrelia burgdorferi was raised 988-1001. in the CSF (1/64: normal < 1/4) by indirect 2 Geny C, Pradat PF, Yulis J, Walter S, Cesaro D, Degos JD. Hypothermia, Wemicke's immunofluorescence, both for IgM (1/16) Metamorphopsia and visual hallucina- encephalopathy and multiple sclerosis. Acta and IgG (1/16), 1-352 (normal < 0-16) by tions restricted to the right visual hemi- Neurol Scand 1992;86:632-4. enzyme linked immunosorbent assay field after a left putaminal haemorrhage 3 Sullivan F, Hutchinson M, Bahandeka S, borrelia Moore RE. Chronic hypothermia in multiple (ELISA) (Immunowell Lyme- sclerosis. J Neurol Neurosurg Psychiatry 1987; BMD); their detection in serum was nega- Metamorphopsia is a rare neurological phe- 50:813-5. tive three weeks later. On 22 October the nomenon in which objects appear distorted 4 Lammens M, Lissoir F, Carton H. patient was extubated. The jerks had totally in form. Many reports have attributed the Hypothermia in three patients with multiple sclerosis. Clin Neurol Neurosurg 1992;91: disappeared and the pains dramatically responsible lesion to the occipitoparietal cor- 117-21. improved. At this time, EMG failed to tex and its related structures.l We report a 5 Ghawche F, Destee A. Hypothermie et scle- detect any myoclonic jerks. Recording of case of left putaminal haemorrhage followed rose en plaques. Un cas avec trois episodes evoked by metamorphopsia and visual hallucina- d'hypothermie transitoire. Rev Neurol Paris peroneal nerve somatosensory poten- 1990;146:767-9. tials and MRI of the spine were unremark- tions restricted to the right visual hemifield. able. On 24 October, the patient was free of The origin of this patient's symptoms was pain and then recovered full strength and considered to be the left optic radiation. normal tendon reflexes. A 63 year old right handed man with a Lyme neuroborreliosis presenting with The clinical features of pain resistant to previous history of hypertension was admit- http://jnnp.bmj.com/ propriospinal myoclonus analgesic agents,' meningoradiculitis with a ted to the hospital with acute right hemi- history of tick bite, and erythema migrans paresis. On admission, his visual field A 60 year old white woman presented with strongly evokes a Lyme neuroborreliosis examination showed a right homonymous an erythema migrans after a tick bite on the confirmed by the CSF findings and detec- hemianopia. There was also a right inferior right thigh on 1 1 July 1995. On 2 October tion of antibodies to Borrelia burgdorferi.2 facial palsy and a right hemiparesis without 1995, she complained of a lumbar pain However, the most dramatic feature was the sensory involvement. The right homony- which radiated to the right thigh. She myoclonic jerks which support the clinical mous hemianopsia disappeared on the third received dextropropoxyphene, paracetamol, diagnosis of propriospinal myoclonus char- day. On the fourth day, he complained that thiocolchicoside, and tetrazepam and then acterised by repetitive, non-rhythmic jerks of the doctor's left cheek seemed to have been on September 27, 2021 by guest. Protected copyright. was additionally treated with codeine, the neck, trunk, both hips, and knees.3 scraped, that the doctor's left hand seemed chlormezanone, and tenoxicam. Despite Sometimes attacks of sustained truncal flex- tortuous, and that some of the fingers of the this, the pains, which prevented sleep, ion are generated by paroxysmal bouts of hand seemed to be missing. He drew a pic- rapidly radiated bilaterally to the low back axial jerks.4 In this type of myoclonus, the ture of what he saw (figlA). Visual field and the abdomen. On 1 lOctober 1995 she discharge arises from a limited segment of examination by confrontation was immedi- presented with flexor non-rhythmic symmet- the spinal cord and then spreads slowly up ately performed but no abnormalities were ric jerks of the trunk, the abdomen, both and down by the involvement of the long found, later confirmed by using Goldmann's hips, and knees evident both sitting and propriospinal pathways.3 The jerks had dis- perimeter. On the next day, he complained, standing, increasing when lying, without appeared at the time of the EMG investiga- "The right half of the curtain in front of me suppression by an effort of will or during tion in our patient. Accordingly, we could suddenly transforms into an animal's face. It voluntary movements. Although the pains not ascertain the possible origin in the tho- rotates there for a while and finally flows to and jerks were atypical, the patient was diag- racic segment of the spinal cord, corre- the right, and then disappears. At the next nosed as having a herniated disc; an epidural sponding to the abdominal and lumbar moment, another face springs up at the very infiltration of dexamethasone (10 mg) gave a muscles, which were painful throughout the portion and. ." He then drew a picture to transient relief of the pains and jerks. A sec- course of the disease and constantly affected illustrate his experience (fig 1B). These phe- ond infiltration was not effective. On 13 by the jerks. To our knowledge, no case of nomena lasted three to four days and then October the patient was admitted to hospi- Lyme neuroborreliosis has been associated disappeared. One month later, he was able tal. The myoclonic jerks had reinforced, with a propriospinal myoclonus. Another to walk without assistance and was dis- occurring sometimes in bursts, occasionally patient had stiffness, painful cramps, and charged from hospital. involving the neck and the shoulders but spasmodic jerks confined to the left leg,5 The laboratory analysis of blood and never the face. The patient was agitated and which suggest a localised myelitis of the urine was within the normal range. Cranial exhausted, and cried on account of the con- spinal intemeurons. Our own strongly CT on admission showed a left putaminal tinuous distressing pains. She was free of evokes the involvement of many spinal seg- haemorrhage without ventricular extension.
Recommended publications
  • WHO Pharmaceuticals Newsletters
    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • Myofascial Pain Syndrome: a Treatment Review Mehul J
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 6-2013 Myofascial pain syndrome: A treatment review Mehul J. Desai George Washington University Vikramjeet Saini Shawnjeet Saini Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons Recommended Citation Desai, M. J., Saini, V., & Saini, S. (2013). Myofascial Pain Syndrome: A Treatment Review. Pain and Therapy, 2(1), 21–36. This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Pain Ther (2013) 2:21–36 DOI 10.1007/s40122-013-0006-y REVIEW Myofascial Pain Syndrome: A Treatment Review Mehul J. Desai • Vikramjeet Saini • Shawnjeet Saini To view enhanced content go to www.paintherapy-open.com Received: September 27, 2012 / Published online: February 12, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT and nonpharmacologic treatments, the authors aim to provide clinicians with a more Myofascial pain syndrome (MPS) is defined as comprehensive knowledge of the interventions pain that originates from myofascial trigger for myofascial pain. points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain Keywords: Analgesics; Anticonvulsants; generators. The appropriate evaluation and Muscle relaxants; Myofascial pain; management of myofascial pain is an important Nonpharmacological treatment; Pain; part of musculoskeletal rehabilitation, and Treatment regional axial and limb pain syndromes.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • [Product Name] 500 Mg + 2 Mg Tablet Paracetamol + Thiocolchicoside
    Package leaflet: Information for the user [Product name] 500 mg + 2 mg Tablet Paracetamol + Thiocolchicoside This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What [Product name] is and what it is used for 2. What you need to know before you take [Product name] 3. How to take [Product name] 4. Possible side effects 5. How to store [Product name] 6. Contents of the pack and other information 1. What [Product name] is and what it is used for This medicine is a muscle relaxant. It is used in adults and adolescents from 16 years old as an adjunctive treatment for painful muscle contractions. It is used for spine-related acute episodes. 2. What you need to know before you take [Product name] Do not take [Product name]: - if you are allergic to paracetamol, thiocolchicoside or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • THIOCOLCHICOSIDE AS MUSCLE RELAXANT: a REVIEW Introduction
    Available Online through International Journal of Pharmacy and Biological Sciences (eISSN: 2230-7605) www.ijpbs.com IJPBS |Volume 1| Issue 3 |JULY-SEPT |2011|364-371 THIOCOLCHICOSIDE AS MUSCLE RELAXANT: A REVIEW A.R Umarkar*, S.R Bavaskar & P.N.Yewale. Shree.Sureshdada Jain Institute of Pharmaceutical & Education and Research Jamner Dist: Jalgaon 424206 *Corresponding Author Email: [email protected] Review Article RECEIVED ON 29-08-2011 ACCEPTED ON 25-09-2011 ABSTRACT Thiocolchicoside, is a synthetic sulphur derivative of colchicoside, a naturally occurring glucosidecontained in the Colchicum autumnale plant Thiocolchicoside has a selective affinity for g-amino-butyric acid (GABA) receptors and acts on themuscular contracture by activating the GABA-nergicinhibitory pathways thereby acting as a potent mus-cle relaxant Thiocolchicoside (Muscoril, Myoril, Neoflax) is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also inhibits glycine receptors with similar potency and nicotinic acetylcholine receptors to a much lesser extent. It has powerful convulsant activity and should not be used in seizure- prone individuals. Mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules by which it interferes with the initiation and amplification of the joint inflammation. THC is a muscle relaxant given by oral in the treatment of arthritis in a usual dose equivalent to 8 mg first day to 12-16mg /day
    [Show full text]
  • The Role of Biotransformation in Drug Discovery and Development
    b Meta olis g m & ru D T o f x o i Journal of Drug Metabolism and l c a o Kebamo et al., J Drug Metab Toxicol 2015, 6:5 n l o r g u y o J Toxicology DOI: 10.4172/2157-7609.1000196 ISSN: 2157-7609 ReviewResearch Article Article OpenOpen Access Access The Role of Biotransformation in Drug Discovery and Development Selamu Kebamo1, Shibiru Tesema2 and Bekesho Geleta3* 1Department of Pharmacology, College of Medical and Health Science, Wollega University, Ethiopia 2Deapartment of Pharmacy, College of Public Health and Medicine Science, Jimma University, Jimma, Ethiopia 3Traditional and Modern Medicine Research, Ethiopian Public Health Institute, Addis Ababa, Ethiopia Abstract Biotransformation is a process by which organic compounds are transformed from one form to another, aided by organisms such as bacteria, fungi and enzymes. It plays a major role and determines the fate of the prospective drugs. Biotransformation must take place only after the drugs reach their specific target site and produce the desired effects. In addition, the nature of the metabolites produced from the drug, must be thoroughly studied; otherwise, the drugs would be rejected during the screening process. Hence, drug metabolism is a major criterion in the high- throughput screening of prospective drugs. Biotransformation has an important role in the determination of the pharmacokinetic parameters like oral bioavailability, drug-drug interaction, clearance and the half-life of the entity within the cell. It is very essential in the toxicity studies too. Biotransformation is used as a valuable strategy to build molecules, similar to parent drug in the drug discovery programme.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • Management of Frozen Shoulder: a Systematic Review and Cost-Effectiveness Analysis
    Health Technology Assessment 2012; Vol. 16: No.111 Acknowledgements Health Technology Assessment 2012; Vol. 16: No. 11 ISSNContribution 1366-5278 of authors ISSN 1366-5278 ReferencesAbstractAppendix 7.2 Sodium hyaluronate Appendix 7.3 Physical therapy GlossaryAppendixAppendix 1 7.4 Acupuncture (with or without physical therapy) SearchAppendix strategies 7.5 Manipulation for effectiveness under review anaesthesia 179 ListBIOSIS ofAppendix abbreviations Previews 7.6 Distension CumulativeAppendix Index7.7 Capsular to Nursing release and Allied Health Literature (CINAHL) ExecutiveCochrane summary Central Register of Controlled Trials (CENTRAL) Clinicaltrials.govBackgroundAppendix 8 CochraneObjectivesStudy quality Database of Systematic Reviews (CDSR) 369 ConferenceMethodsControlled Proceedings trials Citation Index: Science Management of frozen shoulder: DatabaseResultsObservational of Abstracts studies of Reviews of Effects (DARE) EMBASEConclusions a systematic review and HealthFundingAppendix Management 9 Information Consortium (HMIC) HealthWinBUGS Technology code Assessment (HTA) database 373 cost-effectiveness analysis Chapter 1 Latin American and Caribbean Health Sciences Literature (LILACS) BackgroundAppendix 10 Manual, Alternative and Natural Therapy (MANTIS) TheMixed-treatment decision problem comparison 375 NHS Economic Evaluation Database (NHS EED) FrozenNetwork shoulder 1: studies of any intervention (i.e. conservative and invasive) and any quality National Technical Information Service (NTIS) DiagnosisNetwork 2:and studies management of any intervention that were of good or satisfactory quality (i.e. method E Maund, D Craig, S Suekarran, AR Neilson, PASCAL Previousof randomisation systematic was reviews adequate and outcome assessment was blinded) Physiotherapy Evidence Database (PEDro) K Wright, S Brealey, L Dennis, L Goodchild, FocusNetwork of the 3: studiessynthesis of conservative treatments of any quality PREMEDLINE Network 4: studies of conservative treatments that were of good or satisfactory quality (i.e.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs for Acute Low Back Pain Van Der Gaag, Wendelien H; Roelofs, Pepijn Ddm; Enthoven, Wendy Tm; Van Tulder, Maurits W; Koes, Bart W
    VU Research Portal Non-steroidal anti-inflammatory drugs for acute low back pain van der Gaag, Wendelien H; Roelofs, Pepijn Ddm; Enthoven, Wendy Tm; van Tulder, Maurits W; Koes, Bart W published in The Cochrane database of systematic reviews 2020 DOI (link to publisher) 10.1002/14651858.CD013581 document version Publisher's PDF, also known as Version of record document license Article 25fa Dutch Copyright Act Link to publication in VU Research Portal citation for published version (APA) van der Gaag, W. H., Roelofs, P. D., Enthoven, W. T., van Tulder, M. W., & Koes, B. W. (2020). Non-steroidal anti-inflammatory drugs for acute low back pain. The Cochrane database of systematic reviews, 2020(4), 1-151. [CD013581]. https://doi.org/10.1002/14651858.CD013581 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 24.
    [Show full text]